Category Archives: National Standards for Cognitive Testing

National Standards for Cognitive Testing

Early Screening and Diagnosis of Alzheimer’s is key part of NAPA 2025

The U.S. Department of Health and Human Services (HHS) released a draft road map on February 22 that lays out the national strategy to address the rapidly rising rates of Alzheimer’s disease and other types of dementia. There are over 5.4 Million people in the US living with dementia today, and this is expected to… Read More »

The Benefits of Annual Screening for Cognitive Health

Routine health screenings are now common for a variety of conditions like hypertension, diabetes, and glaucoma. Many health insurance plans, including Medicare, provide no cost or low cost health screenings to their members. The main intent behind these preventive health screenings, or wellness screenings, is to provide an early warning system for both consumers and… Read More »

Privacy and Ethics Challenges on Early Diagnosis of Alzheimer’s Disease

A timely article in the medical journal Neurology speaks to some impending issues that millions of patients and physicians will be facing over the next decade, namely the possible early diagnosis of Alzheimer’s Disease in the pre-clinical phase, before functional cognitive impairment is present. New computerized cognitive testing tools and experimental biomarker tests are bringing… Read More »

Moving Cognitive Screening into the Doctor’s Office

A recent article on a new iPad health care application to screen for early signs of Alzheimer’s Disease points to how innovation is beginning to drive research lab tools for cognitive testing into the physician’s office. Developed by Cambridge Cognition, a commercial spin-off from Cambridge University, the screening application is based on Cantab PAL, a… Read More »

Rethinking a Cure for Alzheimer’s Disease

A recent article in Journal of Alzheimer’s Disease discussed several inconvenient facts on the state of Alzheimer’s research, namely that the almost singular focus on amyloid beta protein as the cause of Alzheimer’s Disease (AD) has produced a remarkable string of failures in drug trials that target removal of amyloid beta in the brain. Authored… Read More »